BOCH
LRMR icon

Blue Owl Capital Holdings’s Larimar Therapeutics LRMR Stock Holding History

Blue Owl Capital Holdings’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.91M Buy
+975,700
New +$3.9M 0.51% 31

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Blue Owl Capital Holdings's LRMR Position: Q1 2026 in Review

Blue Owl Capital Holdings increased its Larimar Therapeutics (LRMR) stake by 4.3% in Q1 2026, buying an estimated $1.18M and bringing the position to 7,120,007 shares worth $32M. The position accounts for 8.61% of the portfolio, ranked #2.

Blue Owl Capital Holdings first reported a position in LRMR in Q4 2023 and has held it in 10 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Blue Owl Capital Holdings held 7,120,007 shares of Larimar Therapeutics worth $32M as of Q1 2026.
  • Blue Owl Capital Holdings bought 296,317 Larimar Therapeutics shares in Q1 2026, an estimated $1.18M.
  • Larimar Therapeutics made up 8.61% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #2 holding.
  • Blue Owl Capital Holdings first reported a position in Larimar Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.